null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-acquisition (2020) by Nestlé, Aimmune carried ~$300M convertible notes; low revenue meant debt/EBITDA was effectively negative (pre-profitability).

With floating-rate exposure minimal and fixed convertible notes, a 20% rate rise had limited direct P&L impact; refinancing risk was primary concern.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Peanut sourcing concentrated in US Southeast/Argentina; 2) API manufacturing reliant on single-source CGMP contract manufacturers, likely in North America or Europe.

Palforzia launched primarily in US; EU approval obtained 2020. Euro/USD devaluation is the dominant FX risk; ex-US revenues were negligible pre-Nestlé acquisition.

~90%+ US revenue at commercialization; EU represented primary international market; minimal currency devaluation exposure given early-stage international rollout.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CGMP contract manufacturer for Palforzia drug product likely represents non-substitutable supplier; switching would require FDA re-validation, high lock-in risk.

Specialty pharmaceutical commercial-stage company; cloud dependency for EHR integration and patient registry is moderate, not mission-critical for manufacturing.

30-day cloud termination would disrupt patient support programs and pharmacovigilance systems but would not halt drug manufacturing or distribution immediately.

API coupling risk is low; Aimmune used standard healthcare IT interfaces (HL7/FHIR); no proprietary API lock-in with external vendors identified.

Revenue model is pharmaceutical product sales (Palforzia prescriptions); no investment contract characteristics; Howey Test not applicable, risk index: negligible.

Very High

Patient REMS program data subject to HIPAA primarily; GDPR exposure emerging with EU launch; CCPA applies to California patient data; compliance costs moderate.

Low antitrust risk; Palforzia was first-in-class peanut allergy immunotherapy; no market dominance concern, though Nestlé acquisition drew standard merger review.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional (per-prescription); no subscription model. Specialty pharmacy channel and REMS program created recurring patient cohort but not contractual recurring revenue.

Per-unit prescription revenue via specialty pharmacy distributors; WAC ~$890/month per patient; payer reimbursement negotiations were primary monetization constraint.

WAC ~$10,680/year; pricing benchmarked against SCIT alternatives and allergy biologics; payer pushback on cost-effectiveness was key stress point limiting uptake.

Moderate; first-in-class with clinical differentiation but payer resistance and ICER review constrained pricing power; rated 5/10 given reimbursement hurdles.

Specialty pharma gross margins targeted 70-80%; actual margins compressed by REMS program costs and low initial volumes; estimated realized gross margin ~60-65%.

No free-rider problem; REMS program required prescriber and patient enrollment, creating controlled access; non-compliance risk existed but free-rider leakage minimal.

Revenue growth was sublinear to headcount beyond initial commercial build; sales force of ~150 reps was largely fixed cost; incremental scripts required minimal new hires.

Marginal cost of additional prescriptions was primarily COGS (drug manufacturing) plus specialty pharmacy fees; commercial infrastructure already built, low marginal SG&A.

Not a franchise model; not applicable.

At 10x scale (~50,000 patients), CAC per patient would decline significantly as allergist KOL network saturation reduces rep productivity; estimated CAC ~$3,000-5,000.

No meaningful network effects; clinical outcomes data strengthens label over time but patient growth does not enhance product value for other patients.

AI displacement risk low; Palforzia is a biological drug product requiring physical manufacturing and clinical administration; AI cannot substitute core product delivery.

Moderate resilience; peanut allergy affects ~1.6M US children; parents prioritize child safety spending, but high out-of-pocket costs create recession vulnerability.

Pediatric patients (ages 4-17) with confirmed peanut allergy and their families; approximately 1.6 million addressable US patients at launch.

Prescribing allergists (~6,500 US board-certified allergists); concentrated prescriber base where top 20% of allergists likely drove 80%+ of scripts.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Asset-light manufacturing (outsourced CGMP); capex primarily R&D pipeline and commercial infrastructure; no legacy operations; capital allocated to growth not maintenance.

1326110

AIMT (acquired by Nestlé Health Science in 2020 for $34.50/share cash; no longer publicly traded; discount pre-acquisition reflected commercial execution risk, not commodity supply risk).